Clik here to view.
Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across...
BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress...
View ArticleClik here to view.
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through...
DARMSTADT, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib...
View ArticleClik here to view.
Takeda and The New York Academy of Sciences Announce 2024 Innovators in...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and...
View ArticleClik here to view.
PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in...
LIÈGE, Belgium & GRENOBLE, France PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces completion...
View ArticleClik here to view.
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung...
MENLO PARK, Calif. & CAMBRIDGE, England & SEOUL, South Korea GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, highlighted the presentation of...
View ArticleClik here to view.
ArteraAI and GenesisCare Partner to Launch the First Australian-Based...
SAN FRANCISCO & SYDNEY ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with...
View ArticleClik here to view.
血癌：AOP Health宣布将在美国血液学学会(ASH)第65届年会上发表真性红细胞增多症患者的最新研究成果
圣迭戈 (美国商业资讯)– 位于奥地利维也纳的AOP罕见病药物有限公司（简称“AOP Health”）公布了一项分析结果，旨在评估经单独优化的 Ropeginterferon alfa-2b 给药方案对低风险真性红细胞增多症(PV)患者治疗反应的影响1。这些新数据表明，某些低风险PV患者需要并且能够耐受高剂量的Ropeginterferon alfa-2b，并且不同患者的最佳剂量存在显著差异。...
View ArticleClik here to view.
西班牙和美国的世界知名癌症研究专家联手解决女性癌症研究的关键需求和挑战
达拉斯 (美国商业资讯)– 全球第一大直销护肤彩妆品牌Mary Kay Inc. 1以及该公司赞助的基金会（包括Mary Kay Ash基金会）坚定不移地支持女性癌症研究，资助各种研究计划和项目，向世界知名科学家提供研究资金，并促进临床试验，一切努力的目标是寻找治疗方法。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Clik here to view.
スペインと米国の世界的に有名ながん研究者、女性がん研究の重要なニーズと課題の解決を目指し協力
ダラス （ビジネスワイヤ） — 世界一のスキンケア・カラー化粧品ブランド1であるメアリー・ケイ と、米国のメアリー・ケイ・アッシュ財団をはじめとするメアリー・ケイがスポンサーを務める財団は、治療法の発見の名のもとに、さまざまな研究プログラムやプロジェクトへの資金提供、世界的に有名な科学者への助成金の授与、臨床試験の促進などを通して、女性がん研究への揺るぎない支援を続けています。...
View ArticleClik here to view.
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from...
View ArticleClik here to view.
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection)...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security...
View ArticleClik here to view.
Parse Biosciences完成5000万美元融资，以推动全球业务持续增长
西雅图 (美国商业资讯)– 领先的易获取、可扩展单细胞测序解决方案供应商Parse Biosciences今天宣布已完成总额5000万美元的C轮股权融资和债务融资。Soleus Capital主导了C轮股权融资，Bioeconomy Capital、Janus Henderson Investors、Marshall Wace、Sahsen Ventures和Saras...
View ArticleClik here to view.
パース・バイオサイエンシズ、5000万ドルを資金調達し、世界的な継続的成長を促進
シアトル （ビジネスワイヤ） — アクセス可能でスケーラブルな単一細胞シークエンシング...
View ArticleClik here to view.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on December 15, 2023 the U.S. Food and Drug...
View ArticleClik here to view.
InnoCare Appoints Xin Fu as Chief Financial Officer
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the Company appointed Mr. Xin Fu, who has...
View ArticleClik here to view.
百奥赛图与Ona Therapeutics达成抗体协议，用于针对实体瘤的ADC药物开发
中国北京与西班牙巴塞罗那 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家创新技术驱动新药研发的国际性生物技术公司宣布与Ona Therapeutics（“Ona”），一家专注于发现新生物学来设计晚期癌症药物的西班牙生物技术公司达成抗体评估、选择与授权协议。...
View ArticleClik here to view.
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop...
BEIJING & BARCELONA, Spain Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody...
View ArticleClik here to view.
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today the dosing of its first patient in its Phase 1...
View ArticleClik here to view.
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in...
TOKYO & BASKING RIDGE, N.J. The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca’s...
View Article